Osiris Reports 3rd Quarter 2013 Results: Revenue Up 220%, Strong Balance Sheet, Profitable and Now Cash Flow Positive from Continuing Operations

04-11-2013 Business Wire HealthComments (0)

BiotechnologyOncologyOsiris Therapeutics

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products in orthopedic, sports medicine and wound care markets announced today its financial results for the third quarter of 2013. Highlights and Recent Developments Product revenue for the quarter rose to $6.9 million - up 220% from the third quarter of 2012. Gross margin increased to $5.0 million for the quarter - up 254% from the third quarter of 2012.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top